The estimated Net Worth of James E Flynn is at least $15.3 Milión dollars as of 8 February 2006. James Flynn owns over 43,350 units of Dynavax Technologies stock worth over $15,268,807 and over the last 19 years James sold DVAX stock worth over $0.
James has made over 3 trades of the Dynavax Technologies stock since 2006, according to the Form 4 filled with the SEC. Most recently James bought 43,350 units of DVAX stock worth $246,228 on 8 February 2006.
The largest trade James's ever made was buying 93,040 units of Dynavax Technologies stock on 7 February 2006 worth over $528,467. On average, James trades about 64,130 units every 1 days since 2006. As of 8 February 2006 James still owns at least 1,399,524 units of Dynavax Technologies stock.
You can see the complete history of James Flynn stock trades at the bottom of the page.
James's mailing address filed with the SEC is 780 THIRD AVENUE, 37TH FLOOR, NEW YORK, NY, 10017.
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... a James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: